Europe

R&D

No longer the little fish: How Europe is holding its own thr...

It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.

News

EC clears first treatment for high-risk smouldering multiple...

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX

Digital

Health Technology Assessment – Challenges and opportunities ...

Changes to Health Technology Assessment in Europe offer new opportunities to streamline processes and get innovative treatments to market faster

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Linear visual illustration of nodes in an arrow shape

Enabling Digitally Enhanced Care for Rare Diseases in Europe

Integrating AI and Connected Care Technologies in Lysosomal Storage Disease Patient Journeys

Sales & Marketing

The AI edge: Redefining commercial excellence in 2025

Biopharma companies are increasingly turning to artificial intelligence (AI) to enhance customer-focused commercial strategies, driving more tailored engagement and improved operational eff

News

Chiesi Biotech Center of Excellence opens to strengthen R&D ...

Chiesi Group has today officially launched its new Biotech Center of Excellence, with the aim that it "brings the future of medicine to Parma."